Functional heartburn

Current Treatment Options in Gastroenterology

Volumn 8, Issue 4, 2005, Pages 285-291

  Dickman, Ram ^b   Fass, Ronnie ^a  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANALGESIC AGENT; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; DIAZEPAM; FAMOTIDINE; FEDOTOZINE; GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPRAMINE; KAPPA OPIATE RECEPTOR AGONIST; LOXIGLUMIDE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OMEPRAZOLE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; PUMAPRAZOLE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; AGITATION; ANTIREFLUX OPERATION; CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DIET THERAPY; DROWSINESS; DRUG COST; DRUG DOSE REGIMEN; DYSPEPSIA; ENDOSCOPIC THERAPY; FLATULENCE; FUNCTIONAL HEARTBURN; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART ARRHYTHMIA; HEART BLOCK; HEARTBURN; HUMAN; HYPONATREMIA; HYPOTENSION; LIFESTYLE; LOW DRUG DOSE; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PAIN; PSYCHOTHERAPY; REVIEW; SEIZURE THRESHOLD; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; SYNCOPE; TREATMENT OUTCOME; TREMOR; URINE RETENTION; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 24044530053     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0021-0     Document Type: Review

References (30)

1. Fass R, Tougas G: Functional heartburn: the stimulus, the pain, and the brain. Gut 2002, 51:885-892.
2. Klinkenberg-Knol EC, Castell DO: Clinical spectrum and diagnosis of gastroesophageal reflux disease. In The Esophagus. 3rd ed. Castell DO, Richter JE, editors. Philadelphia: Lippincott Williams and Wilkins 1999, 75-380.
3. Lind T, Havelund T, Carlsson R: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997, 32:974-979.
4. Jones RH, Hungin ADS, Phillips J: Gastroesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995, 1:14-154.
5. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC: Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997, 92:1997-2000.
6. Johnsson F, Weywadt L, Solhaug JH, et al.: One-week omeprazole treatment in the diagnosis of gastrooesophageal reflux disease. Scand J Gastroenterol 1998, 33:15-20.
7. Fass R, Ofman JJ, Gralnek IM, Johnson C, et al.: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999, 159:2161-2168.
8. Mayer E, Naliboff B, Lee O, Munakata J, Chang L: Review article: gender-related differences in functional gastrointestinal disorders. Aliment Pharmacol Ther 1999, 13:65-69.
9. Martinez SD, Malagon IB, Garewal HS, et al.: Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003, 17:537-545.
10. Weiner GJ, Morgan TM, Copper JB, et al.: The symptom index: A clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988, 83:358-361.
11. Meyer JH, Lembo A, Elashoff JD, et al.: Duodenal fat intensifies the perception of heartburn. Gut 2001, 49:624-628.
12. Waring JP: Nonerosive reflux disease. Semin Gastrointest Dis 2001, 12:33-37.
13. Fass R, Naliboff B, Higa L, et al.: Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998, 115:1363-1373.
14. Hobson AR, Matthews P, Furlong P, Aziz Q: The role of esophageal afferent pathway sensitivity in nonerosive reflux disease (abstract). Gastroenterology 2004, 126:A-18, 128.
15. Rodriguez-Stanley S, Robinson M, Earnest DL, et al.: Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol 1999, 94:628-631.
16. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB, Jr: Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005, 50:81-85.
17. Trimble KC, Pryde A, Heading RC: Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995, 37:7-12.
18. Schindlbeck NE, Wiebecke B, Klauser AG, et al.: Diagnostic value of histology in non-erosive gastrooesophageal reflux disease. Gut 1996, 39:151-154.
19. Frazzoni M, De Micheli E, Zentilin P, Savarino V: Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004, 20:81-88.
20. Watson RG, Tham TC, Johnston BT, McDougall NI: Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the "sensitive esophagus". Gut 1997, 40:587-590.
21. Richter JE, Campbell DR, Kahrilas PJ, et al.: Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000, 160:1803-1809.
22. Fass R, Murthy U, Hayden CW, et al.: Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-esophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000, 14:1595-1603.
23. Fass R, Quan SF, O'Connor GT, et al.: Predictors of heartburn during sleep in a large prospective cohort study. Chest 2005, 127:1658-1666.
24. Marrero JM, de Caestecker JS, Maxwell JD: Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. Gut 1994, 35:447-450.
25. Rodriguez-Stanley S, Ciociola AA, Zubaidi S, et al.: A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn. Aliment Pharmacol Ther 2004, 20:975-982.
26. Clouse RE, Lustman PJ, Eckert TC, et al.: Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987, 92:1027-1036.
27. Cannon RO, 3rd, Quyyumi AA, Mincemoyer R, et al.: Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994, 330:1411-1417.
28. Fenton P, Terry ML, Galloway KD, et al.: Is there a role for laparoscopic fundoplication in patients with non-erosive reflux disease (NERD)? (abstract). Gastroenterology 2000, 18:A481, 2600.
29. Sarkar S, Aziz Q, Woolf CJ, et al.: Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000, 356:1154-1159.
30. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ: The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000, 14:1503-1509.